Marksans Pharma

Home

Career

Contact Us

	Businesses

	Formulation / Strategic Business Unit / Criticare

Globally Oncology has been found to be the fastest growing therapeutic segment currently boasting a growth rate of 27% Marksans is carving out a niche position in Oncology market with molecules which are based on drug delivery system Biotechnology drugs, antineoplastics and Immunomodulators are the front runners for the division. Criticare also has products which are Life saving. As the Oncology and Critical Care products are gaining grounds, plans are afoot to have Separate divisions for Oncology and Critical Care. The company also has plans to acquire Biotechnology Know-how and start manufacturing Human Recombinant Drugs in India and become a major player in Biotechnology by 2010.

Current basket of products

	Gemcel - Gemcitabine : The incredible saviour
	Docemark- Docetaxel : Offers a new lease of life
	Paclimark - Paclitaxel : The Versatile
	Oplax - Oxaliplatin : The superior platinum edge
	Stineugen - Filgrastim : Stimulates Neutrophil generation
	Rubimark - Epirubicin : A turn that matters
	Markferon - Interferon alfa 2b : The power to enhance life
	Markparin - Enoxaparin : A complete solution
	Pizosans - Piperacillin + Tazobactum : The Guardian Angel for your patients
	Sanmero - Meropenum : The antibiotic with "Killer Instinct"

Products in Pipeline

	Capest - Capecitabine : For metastatic Breast and Colorectal Cancer
	Imimark - Imatinib mesylate : For Chronic Myeloid Leukemia
	Letrozole : Hormonal Therapy for Breast Cancer
	Geftinib : For metastatic Lung cancer

Formulation

Plants and Manufacturing

International Operations

Domestic / Strategic Business Unit

	Mark Remedies

	Criticare

	Cerebella

	Zenmark

Active Pharmaceuticals Ingredient

The Contract Research & Manufacturing Services

In Licensing

Business Development

Field Force